Talk about your emotions coming into this week after winning in 2023… “You definitely walk in with more confidence. I walked ...
U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority review with a PDUFA date of July 22, 2025 ...